Zydus Lifesciences Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹1,13,198 Cr
- Book Value
- ₹269.7
- Stock P/E
- 20.9
- Dividend Yield
- 0.09%
- ROE
- 21.3%
- ROCE
- 21.1%
- PEG Ratio
- 1.11
- EV/EBITDA
- 13.8
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Zydus Lifesciences share price today
Zydus Lifesciences (NSE: ZYDUSLIFE) is the value pick in our large-pharma coverage — and it is tagged accumulate in our research universe for exactly that reason. A 31% operating margin, 21% returns on equity and capital, an 18.8% five-year profit CAGR — priced at 20.9× earnings with a PEG of 1.1, while peers of similar quality trade at 35–40×.
The discount has reasons: heavier US generics exposure (price-erosion risk), and a debt-to-equity of 0.46 that peers don’t carry. The question is whether those reasons justify a 45% valuation gap. We don’t think so, at the right entry.
What the discount overlooks
Zydus is more than a US generics house. The domestic branded business compounds quietly. Vaccines (including India’s first indigenous ZyCoV-D platform know-how) and biologics add depth. A specialty ladder — Saroglitazar in liver disease is the flagship — offers genuine innovation optionality that a 21× multiple pays nothing for. Meanwhile the US business keeps winning limited-competition launches (transplant, oncology niches) that carry generic labels but specialty economics for their exclusivity windows.
Watch-items: US price erosion each quarter, FDA outcomes across its plants, the debt trajectory (0.46 D/E is manageable, not pristine), and whether Saroglitazar’s global trials convert optionality into earnings.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹1,13,198 Cr |
| P/E (TTM) | 20.9 |
| EV/EBITDA | 13.8 |
| Operating margin | 31.2% |
| ROE / ROCE | 21.3% / 21.1% |
| Debt to equity | 0.46 |
| Sales CAGR (5y) | 12.5% |
| Profit CAGR (5y) | 18.8% |
| Promoter holding | 75.0% (zero pledged) |
| EPS (TTM) | ₹54.2 |
Zydus Lifesciences share price target 2026 to 2030
EPS base ₹54.2 (TTM). Bear: US price erosion accelerates and a plant hits FDA trouble — 6% growth, multiple stays 17×. Base: 12% growth, modest re-rate to 24× as debt reduces. Bull: specialty (Saroglitazar) lands and the discount closes — 16% growth at 30×.
| Year | Bear (17×, +6%) | Base (24×, +12%) | Bull (30×, +16%) |
|---|---|---|---|
| 2026 | ₹975 | ₹1,455 | ₹1,885 |
| 2027 | ₹1,035 | ₹1,630 | ₹2,190 |
| 2028 | ₹1,095 | ₹1,825 | ₹2,540 |
| 2029 | ₹1,165 | ₹2,045 | ₹2,945 |
| 2030 | ₹1,235 | ₹2,290 | ₹3,420 |
From ₹1,130, the base case is ≈ +103% over four and a half years — a double from a stock whose multiple starts at 21, not 60. The bear case is roughly +9%: cheap entry prices are their own risk management. This is why the accumulate tag exists — the arithmetic works even without heroic assumptions.
Reasons to own Zydus Lifesciences (at the right price)
- The valuation: quality-comparable pharma at 21× when the peer set trades at 35×+ — PEG 1.1.
- 31% operating margin — the P&L already runs at premium-pharma quality.
- Specialty optionality (Saroglitazar, biologics, vaccines) priced at zero.
- Limited-competition US launches keep surprising against the “generics erosion” narrative.
- 75% promoter holding, zero pledge.
The risks: US generic pricing is the permanent headwind, FDA risk applies to every Indian pharma plant, and leverage (0.46 D/E) removes some margin for error that debt-free peers keep.
Should you buy at the current price?
The live buy range below is for members — the zone where we would actually accumulate.
FAQ
What is the Zydus Lifesciences share price target for 2030? Base case ≈ ₹2,290 (24× on 12% compounded growth), bear ≈ ₹1,235, bull ≈ ₹3,420. Arithmetic above.
Why is Zydus cheaper than Sun Pharma or Abbott India? Higher US generics mix (price-erosion exposure) and some balance-sheet leverage. The market prices those risks heavily — our view is too heavily, given the margin profile and specialty pipeline.
What is Saroglitazar and why does it matter? A Zydus-discovered drug for fatty-liver disease (MASH) — one of pharma’s largest unmet markets. Global success would re-rate the company from generics maker to innovator; the current price assumes nothing for it.
When are Zydus’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.